Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H21N5O3 |
Molecular Weight | 367.4017 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2NC3=C(C=CC4=C3C(=NN4CCCN(C)C)C2=C1)[N+]([O-])=O
InChI
InChIKey=HZCWPKGYTCJSEB-UHFFFAOYSA-N
InChI=1S/C19H21N5O3/c1-22(2)9-4-10-23-15-7-8-16(24(25)26)19-17(15)18(21-23)13-11-12(27-3)5-6-14(13)20-19/h5-8,11,20H,4,9-10H2,1-3H3
Molecular Formula | C19H21N5O3 |
Molecular Weight | 367.4017 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Pyrazoloacridine is a pyrazolo[3,4,5-kl]acridine derivative patented by Warner-Lambert Co. as an anticancer agent. Pyrazoloacridine acts as topoisomerase I and II inhibitor that decrease the formation of topoisomerase-DNA adducts. In vitro experiments, Pyrazoloacridine shows efficacy against multidrug-resistant neuroblastoma doxorubicin-resistant human colon carcinoma and breast cancer cell lines. In clinical trials, Pyrazoloacridine demonstrates moderate efficacy in metastatic breast cancer and a high level of adverse events. The dose-limiting toxicity was grade 4 neutropenia. Other grade 3 and 4 toxicities include vomiting, nausea, neurotoxicity, fatigue, and anemia.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. | 2000 May |
|
Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study. | 2002 Aug |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12201497
three-hour infusion at 750 mg/m^2 every 21 days.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 20:14:49 GMT 2023
by
admin
on
Fri Dec 15 20:14:49 GMT 2023
|
Record UNII |
L24XJN68OW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2161
Created by
admin on Fri Dec 15 20:14:49 GMT 2023 , Edited by admin on Fri Dec 15 20:14:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
99009-20-8
Created by
admin on Fri Dec 15 20:14:49 GMT 2023 , Edited by admin on Fri Dec 15 20:14:49 GMT 2023
|
PRIMARY | |||
|
L24XJN68OW
Created by
admin on Fri Dec 15 20:14:49 GMT 2023 , Edited by admin on Fri Dec 15 20:14:49 GMT 2023
|
PRIMARY | |||
|
DB12549
Created by
admin on Fri Dec 15 20:14:49 GMT 2023 , Edited by admin on Fri Dec 15 20:14:49 GMT 2023
|
PRIMARY | |||
|
339455
Created by
admin on Fri Dec 15 20:14:49 GMT 2023 , Edited by admin on Fri Dec 15 20:14:49 GMT 2023
|
PRIMARY | |||
|
627168
Created by
admin on Fri Dec 15 20:14:49 GMT 2023 , Edited by admin on Fri Dec 15 20:14:49 GMT 2023
|
PRIMARY | |||
|
DTXSID301316714
Created by
admin on Fri Dec 15 20:14:49 GMT 2023 , Edited by admin on Fri Dec 15 20:14:49 GMT 2023
|
PRIMARY | |||
|
C1564
Created by
admin on Fri Dec 15 20:14:49 GMT 2023 , Edited by admin on Fri Dec 15 20:14:49 GMT 2023
|
PRIMARY | NCIT | ||
|
366140
Created by
admin on Fri Dec 15 20:14:49 GMT 2023 , Edited by admin on Fri Dec 15 20:14:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |